<DOC>
	<DOCNO>NCT00211120</DOCNO>
	<brief_summary>The purpose study compare outcomes patient chronic kidney disease ( CKD ) randomly assign 2 treatment group , differ target hemoglobin level . This study test primary hypothesis level anemia correction weekly dosing PROCRITÂ® ( Epoetin alfa ) patient chronic kidney disease decrease mortality cardiovascular morbidity .</brief_summary>
	<brief_title>Correction Hemoglobin Outcomes Renal Insufficiency ( CHOIR )</brief_title>
	<detailed_description>This prospective , open-label , randomize , multi-center study patient CKD . Patients meet selection criterion randomly assign one two treatment arm : GROUP A : PROCRIT® ( Epoetin alfa ) therapy direct maintain hemoglobin level close 13.5 g/dL possible ( may slightly high low ) GROUP B : PROCRIT® ( Epoetin alfa ) therapy direct maintain hemoglobin level close 11.3 g/dL possible ( may slightly high low ) . Patients receive weekly dos PROCRIT® ( Epoetin alfa ) . Subsequent dose PROCRIT® give weekly need dose adjustment make maintain hemoglobin ( Hb ) close target level possible initiation Renal Replacement Therapy ( RRT ) 36 month , whichever come first . The purpose study compare outcomes patient CKD randomly assign 2 treatment group , differ target hemoglobin level . This study test primary hypothesis level anemia correction weekly dosing PROCRIT® ( Epoetin alfa ) patient chronic kidney disease decrease mortality cardiovascular morbidity . Patients receive start dose PROCRIT® 10,000 Units ( U ) subcutaneously ( SC ) 1x / week . After 3 weekly dos , subsequent dos dose interval PROCRIT® , maximum dose 20,000 U 36 month , adjust base assessment two recent hemoglobin value .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Chronic Kidney Disease : Glomerular filtration rate ( GFR ) &gt; 15 mL/min &gt; 50 mL/min calculate central lab . HB &lt; 11 g/dL upon study enrollment . The GFR assessment patient eligibility determine use formula derive Modification Diet Renal Disease ( MDRD ) Study . Pregnant lactate woman Presence uncontrolled hypertension Known hypersensitivity mammalian cellderived product human albumin Active gastrointestinal bleeding Iron overload define transferrin saturation &gt; 70 % ferritin &gt; 1000 ng/mL History frequent blood transfusion past 6 month Unstable angina angina pectoris rest Severe chronic obstructive pulmonary disease require routine use supplemental oxygen Severe liver dysfunction define international normalized ratio &gt; 2.0 , cause anticoagulant Severe malnutrition Active hematological disease ( eg , sickle cell anemia , thalassemia ) Active malignancy ( usually define malignancy require current chemotherapy radiotherapy ) Patients current seizure disorder activity Patients currently receive RRT ( patient dialysis kidney transplant ) Patients receive Epoetin Alpha within 6 week prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Low Blood Count</keyword>
	<keyword>Chronic Kidney Failure</keyword>
	<keyword>Chronic Kidney Disease</keyword>
</DOC>